Threshold Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Threshold Pharmaceuticals
Starting stock price: $3.41
Ending stock price: $0.53
Percent Change: -84.46%
Details: Threshold had a tough time of it in 2006, and the situation didn't improve in 2007 when the company halted a Phase II trial of glufosfamide for small cell lung cancer after it found that patients weren't responding to the drug. Just two weeks later Threshold chopped its 44-person workforce down to 32, concentrating on its hypoxia-activated prodrug program and the ongoing clinical trials of glufosfamide for pancreatic cancer and Phase II for ovarian cancer. Earlier this year the company said the pancreatic cancer trial would continue, but the ovarian cancer trial has been abandon due to lack of efficacy.
More News:
Threshold slashes staff in effort to cut burn rate. Report
Threshold halts lung cancer study. Report
Threshold delays release of glufosfamide analysis. Report
Threshold slashes staff in wake of quarterly loss. Report
Threshold shares drop after Phase III suspension. Report
More stories about Threshold Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: